Aspirin
- Generic Name
- Aspirin
- Brand Names
- Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
- Drug Type
- Small Molecule
- Chemical Formula
- C9H8O4
- CAS Number
- 50-78-2
- Unique Ingredient Identifier
- R16CO5Y76E
- Background
Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .
...
- Indication
Pain, fever, and inflammation
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
- Associated Therapies
- Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention
Pharmaceuticals in pregnancy: a multifaceted challenge in Australia
Supply constraints for critical medications in Australia highlight pregnant women's vulnerability to medication shortages, exacerbated by their exclusion from clinical trials and sponsor-driven drug registration. Proposed solutions include creating a publicly funded entity to manage critical medications, reforming the drug safety categorization system, and exploring novel strategies to include pregnant women in therapeutic trials.
Samjin Pharm holds symposium to mark 17th anniversary of launching antiplatelet drug
Samjin Pharmaceutical held a symposium at the Grand Hyatt Seoul on Aug. 24-25 to mark the 17th anniversary of Platless Tab (clopidogrel) launch, focusing on clinical research updates. Over 100 cardiologists attended, with lectures on long-term maintenance after coronary stenting and the HOST-PREVENTION study, which aims to expand clopidogrel's therapeutic area to primary prevention therapy.
Drug-Coated Balloon Angioplasty With Rescue Stenting Versus Intended Stenting for the ...
The REC-CAGEFREE I trial found that PCI with paclitaxel-coated balloon was inferior to traditional DES PCI for multiple CV outcomes at 2 years among patients with de novo lesions. The trial aimed to assess the safety and efficacy of a paclitaxel-coated balloon (DCB) compared to drug-eluting stent (DES) implantation. The study involved 2,272 patients randomized to either DCB or DES, with follow-up for 734 days. The primary outcome showed DCB was not noninferior to DES (6.4% vs. 3.4%, p for noninferiority = 0.65), with inferior outcomes particularly in larger vessels. Small vessel disease showed comparable outcomes between DCB and DES.
Research suggests flexible approach to antiplatelet management after coronary drug-eluting
In patients with coronary drug-eluting stents undergoing non-cardiac surgery, aspirin monotherapy showed no difference in ischemic outcomes or major bleeding compared to no antiplatelet therapy. The ASSURE DES trial, involving 926 patients, found similar rates of primary outcomes and major bleeding, with a slight increase in minor bleeding in the aspirin group. The low event rate suggests a need for further research in higher-risk scenarios.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath